SOURCE: TheSUBWAY.com

July 11, 2006 09:57 ET

TheSUBWAY.com Posts Stock Pick List: Nigerian President Olusegun Obasanjo Launches Xechem's Sickle Cell Drug!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- July 11, 2006 -- TheSUBWAY.com names the following stocks to its Stock Pick List: Xechem International Inc. (OTCBB: XKEM), Valentis, Inc. (NASDAQ: VLTS), SIRIUS Satellite Radio (NASDAQ: SIRI), JDSU (NASDAQ: JDSU).

Xechem International, Inc.'s (OTCBB: XKEM) subsidiary, Xechem Pharmaceuticals Nigeria, just announced the successful launch of its new Sickle Cell drug, NICOSAN™, at a ceremony held on July 6th at Xechem Park, SHESTCO Complex, Abuja, Nigeria. The launching ceremony that was presided over by Nigeria's President, Chief Olusegun Obasanjo, was broadcasted live throughout Nigeria. Days earlier, the drug was approved by Nigeria's drug and regulatory authority, the National Agency for Food and Drug Administration and Control (NAFDAC).

Xechem has obtained the exclusive worldwide rights to manufacture, market and sell NICOSAN™ under a licensing agreement with Nigeria's National Institute for Pharmaceutical Research and Development (NIPRD), a federal governmental agency whose scientists are credited with developing the drug.

Other stocks highlighted include Valentis, Inc. (NASDAQ: VLTS): Stock Watch List, down 1% on 2 million shares, SIRIUS Satellite Radio (NASDAQ: SIRI): Stock Watch List, up 1% on 2 million shares, JDSU (NASDAQ: JDSU): Stock Focus List, up 1% on 1 million shares): Stock Watch List, up 1% on 4 million shares.

"Stocks have been hard-pressed to pick a direction in trading lately, going on a tear for a few days, only to see those gains wane in the next several sessions. The Dow Jones Industrial Average is, in fact, hovering not far above the level it was at when the Federal Reserve began raising rates a year ago." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated thirty thousand dollars for XKEM. CRG was compensated one hundred twenty thousand dollars in past compensation for XKEM. CRG intends to sell its shares. CRG has sold approximately zero XKEM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information

  • Chuck Tamburello
    Phone: 954-217-8555
    Fax: 954-217-1500